Analytical Data
-
Gene name
AaH
- Application
-
Alternative Names
AaH II Short name:AaHII Neurotoxin 2
-
Species
Androctonus australis
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01484
-
Expression Region
20-83aa
-
Molecular Weight
23.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of AaH recombinant protein is rooted in the need to understand the biological properties and potential applications of proteins derived from the venom of the Androctonus australis hector scorpion. Research on scorpion venom has gained significant attention due to its diverse pharmacological effects and the unique bioactive components it contains, including proteins, peptides, and enzymes. AaH, a major component of this venom, is known for its neurotoxic effects, which can lead to various physiological responses in prey and can have implications for human health. By producing AaH as a recombinant protein, scientists aim to overcome challenges related to its extraction and purification from natural sources, enabling detailed studies of its structure, function, and potential therapeutic uses. Additionally, recombinant technology facilitates the modification of the protein to enhance its properties or reduce its toxicity, paving the way for novel biomedical applications, such as analgesics, treatments for autoimmune diseases, or as tools in molecular biology. As such, the investigation of AaH recombinant protein holds promise for advancing both basic research in toxinology and practical applications in medicine and pharmacology.
